[1] GBD 2016 Stroke Collaborators. Global，regional，

and national burden of stroke，1990-2016：a

systematic analysis for the global burden of disease

study 2016[J]. Lancet Neurol，2019，18（5）：439-

458.

[2] ZHOU M，WANG H，ZENG X，et al. Mortality，

morbidity，and risk factors in China and its provinces，

1990-2017：a systematic analysis for the Global

Burden of Disease Study 2017[J]. Lancet，2019，394

（10204）：1145-1158.

[3] The National Institute of Neurological Disorders

and Stroke rt-PA Stroke Study Group. Tissue

plasminogen activator for acute ischemic stroke[J].

N Engl J Med，1995，333（24）：1581-1587.

[4] HACKE W，KASTE M，BLUHMKI E，et al.

Thrombolysis with alteplase 3 to 4.5 hours after

acute ischemic stroke[J]. N Engl J Med，2008，359

（13）：1317-1329.

[5] MA H，CAMPBELL B C V，PARSONS M W，et

al. Thrombolysis guided by perfusion imaging up to

9 hours after onset of stroke[J]. N Engl J Med，2019，

380（19）：1795-1803.

[6] CAMPBELL B C V，MA H，RINGLEB P A，et

al. Extending thrombolysis to 4.5-9 h and wake-up

stroke using perfusion imaging：a systematic review

了新思路[44-45]。卒中后肢体功能障碍为家庭和社

会带来了巨大负担，期待有更多的研究寻找更

有效的康复方式。

回眸2019，科技的力量推动着脑血管病研

究的步伐不断向前。2019年，世界科技界的进

展也令人瞩目，2月份首张黑洞照片公布；年中，

首张量子纠缠照片公布，科学家在宏观和微观

领域都在不断地进行探索。谷歌的量子计算

机实现“量子霸权”；清华大学异构融合类脑

计算芯片登上Nature 杂志的封面；马斯克宣布

“脑机接口”装置的突破……各领域新技术的发

展，似乎在提示我们，2020年后真的是“未来已

至”吗？未来的技术会在多大程度上促进医学

探索，又会在多大程度上误导医学的发展？

2020年，跨入未来，对于卒中领域的学者，

需要学习利用科技，引领科技在正确的道路上

推动脑血管病研究和临床实践的发展。

and meta-analysis of individual patient data[J].

Lancet，2019，394（10193）：139-147.

[7] DAVIS S M，DONNAN G A，PARSONS M W，et

al. Effects of alteplase beyond 3 h after stroke in

the echoplanar imaging thrombolytic evaluation

trial（EPITHET）：a placebo-controlled randomised

trial[J]. Lancet Neurol，2008，7（4）：299-309.

[8] AMIRI H，BLUHMKI E，BENDSZUS M，et

al. European Cooperative Acute Stroke Study-4：

extending the time for thrombolysis in emergency

neurological deficits ECASS-4：ExTEND[J]. Int J

Stroke，2016，11（2）：260-267.

[9] TURK A S 3rd，SIDDIQUI A，FIFI J T，et al.

Aspiration thrombectomy versus stent retriever

thrombectomy as first-line approach for large vessel

occlusion（COMPASS）：a multicentre，randomised，

open label，blinded outcome，non-inferiority trial[J].

Lancet，2019，393（10175）：998-1008.

[10] YOO A J，KHATRI P，MOCCO J，et al. Impact of

thrombus length on outcomes after intra-arterial

aspiration thrombectomy in the THERAPY trial[J].

Stroke，2017，48（7）：1895-1900.

[11] LAPERGUE B，BLANC R，GORY B，et al. Effect

of endovascular contact aspiration vs stent retriever

on revascularization in patients with acute ischemic

stroke and large vessel occlusion：the ASTER

randomized clinical trial[J]. JAMA，2017，318（5）：

443-452.

[12] NOGUEIRA R G，FREI D，KIRMANI J F，et al.

Safety and efficacy of a 3-Dimensional stent retriever

with aspiration-based thrombectomy vs aspirationbased

thrombectomy alone in acute ischemic stroke

intervention：a randomized clinical trial[J]. JAMA

Neurol，2018，75（3）：304-311.

[13] HART R G，DIENER H C，COUTTS S B，et al.

Embolic strokes of undetermined source：the case for

a new clinical construct[J]. Lancet Neurol，2014，13

（4）：429-438.

[14] HARLOFF A，SCHLACHETZKI F. Rivaroxaban

for stroke prevention after embolic stroke of

undetermined source[J]. N Engl J Med，2018，379

（10）：986-987.

[15] DIENER H C，SACCO R L，EASTON J D，et al.

Dabigatran for prevention of stroke after embolic

stroke of undetermined source[J]. NEJM，2019，380

（20）：1906-1917.

[16] PACIARONI M，KAMEL H. Do the results of RESPECT

ESUS call for a revision of the embolic

stroke of undetermined source definition?[J]. Stroke，

2019，50（4）：1032-1033.

[17] HEALEY J S，GLADSTONE D J，SWAMINATHAN B，et al. Recurrent stroke with

rivaroxaban compared with aspirin according to

predictors of atrial fibrillation：secondary analysis of

the NAVIGATE ESUS randomized clinical trial[J].

JAMA neurol，2019，76（7）：764-773.

[18] NTAIOS G，SWAMINATHAN B，BERKOWITZ

S D，et al. Efficacy and safety of rivaroxaban versus

aspirin in embolic stroke of undetermined source

and carotid atherosclerosis[J]. Stroke，2019，50（9）：

2477-2485.

[19] AMARENCO P，GOLDSTEIN L B，SZAREK

M，et al. Effects of intense low-density lipoprotein

cholesterol reduction in patients with stroke or

transient ischemic attack：the Stroke Prevention

by Aggressive Reduction in Cholesterol Levels

（SPARCL）trial[J]. Stroke，2007，38（12）：3198-

3204.

[20] AMARENCO P，KIM J S，LABREUCHE J，et al.

A comparison of two LDL cholesterol targets after

ischemic stroke[J]. N Engl J Med，2020，382（1）：9.

[21] KRISHNAMURTHI R V，FEIGIN V L，

FOROUZANFAR M H，et al. Global and regional

burden of first-ever ischaemic and haemorrhagic

stroke during 1990-2010：findings from the Global

Burden of Disease Study 2010[J/OL]. Lancet

Glob Health，2013，1（5）：e259-e281. https：//doi.

org/10.1016/S2214-109X（13）70089-5.

[22] KEEP R F，HUA Y，XI G. Intracerebral

haemorrhage：mechanisms of injury and therapeutic

targets[J]. Lancet Neurol，2012，11（8）：720-731.

[23] HANLEY D F，THOMPSON R E，ROSENBLUM

M，et al. Efficacy and safety of minimally invasive

surgery with thrombolysis in intracerebral

haemorrhage evacuation（MISTIE Ⅲ）：a

randomised，controlled，open-label，blinded

endpoint phase 3 trial[J]. Lancet，2019，393（10175）：

1021-1032.

[24] KURAMATSU J B，BIFFI A，GERNER S T，et

al. Association of surgical hematoma evacuation vs

conservative treatment with functional outcome in

patients with cerebellar intracerebral hemorrhage[J].

JAMA，2019，322（14）：1392-1403.

[25] PETERS S A，HUXLEY R R，WOODWARD

M. Diabetes as a risk factor for stroke in women

compared with men：a systematic review and

meta-analysis of 64 cohorts，including 775，385

individuals and 12，539 strokes[J]. Lancet，2014，383

（9933）：1973-1980.

[26] YONG M，KASTE M. Dynamic of hyperglycemia

as a predictor of stroke outcome in the ECASS-Ⅱ

trial[J]. Stroke，2008，39（10）：2749-2755.

[27] BRUNO A，KENT T A，COULL B M，et al.

Treatment of hyperglycemia in ischemic stroke

（THIS）：a randomized pilot trial[J]. Stroke，2008，

39（2）：384-389.

[28] GRAY C S，HILDRETH A J，SANDERCOCK P

A，et al. Glucose-potassium-insulin infusions in the

management of post-stroke hyperglycaemia：the

UK Glucose Insulin in Stroke Trial（GIST-UK）[J].

Lancet Neurol，2007，6（5）：397-406.

[29] POWERS W J，RABINSTEIN A A，ACKERSON

T，et al. Guidelines for the early management of

patients with acute ischemic stroke：2019 update

to the 2018 guidelines for the early management of

acute ischemic stroke：a guideline for healthcare

professionals from the American Heart Association/

American Stroke Association[J/OL]. Stroke，2019，

50（12）：e344-e418. https：//doi.org/10.1161/

STR.0000000000000211.

[30] 中华医学会神经病学分会. 中国急性缺血性脑卒中

诊治指南2018[J]. 中华神经科杂志，2018，51（9）：

666-682.

[31] JOHNSTON K C，BRUNO A，PAULS Q，et al.

Intensive vs standard treatment of hyperglycemia

and functional outcome in patients with acute

ischemic stroke：the SHINE randomized clinical

trial[J]. JAMA，2019，322（4）：326-335.

[32] The SPRINT MIND Investigators for the SPRINT

Research Group，WILLIAMSON J D，PAJEWSKI

N M，et al. Effect of intensive vs standard blood

pressure control on probable dementia：a randomized

clinical trial[J]. JAMA，2019，321（6）：553-561.

[33] YAFFE K. Prevention of cognitive impairment with

intensive systolic blood pressure control[J]. JAMA，

2019，321（6）：548-549.

[34] HACHINSKI V，EINHAUPL K，GANTEN D，et al.

Preventing dementia by preventing stroke：the Berlin

Manifesto[J]. Alzheimers Dement，2019，15（7）：

961-984.

[35] SABIA S，FAYOSSE A，DUMURGIER J，et al.

Association of ideal cardiovascular health at age 50

with incidence of dementia：25 year follow-up of

Whitehall Ⅱ cohort study[J/OL]. BMJ，2019，366：

l4414. https：//doi.org/10.1136/bmj.l4414.

[36] The SPRINT MIND Investigators for the SPRINT

Research Group，NASRALLAH I M，PAJEWSKI

N M，et al. Association of intensive vs standard

blood pressure control with cerebral white matter

lesions[J]. JAMA，2019，322（6）：524-534.

[37] The ENOS Trial Investigators. Efficacy of nitric

oxide，with or without continuing antihypertensive

treatment，for management of high blood pressure in acute stroke（ENOS）：a partial-factorial randomised

controlled trial[J]. Lancet，2015，385（9968）：617-

628.

[38] The RIGHT-2 Investigators. Prehospital transdermal

glyceryl trinitrate in patients with ultra-acute

presumed stroke（RIGHT-2）：an ambulance-based，

randomised，sham-controlled，blinded，phase 3

trial[J]. Lancet，2019，393（10175）：1009-1020.

[39] RODGERS H，BOSOMWORTH H，KREBS H

I，et al. Robot assisted training for the upper limb

after stroke（RATULS）：a multicentre randomised

controlled trial[J]. Lancet，2019，394（10192）：51-

62.

[40] STINEAR C M，BYBLOW W D，ACKERLEY S

J，et al. PREP2：a biomarker-based algorithm for

predicting upper limb function after stroke[J]. Ann

Clin Transl Neurol，2017，4（11）：811-820.

[41] CRAMER S C，WOLF S L，ADAMS H P，et al.

Stroke recovery and rehabilitation research：issues，

opportunities，and the National Institutes of Health

StrokeNet[J]. Stroke，2017，48（3）：813-819.

[42] LOHSE K R，LANG C E，BOYD L A. Is more

better? Using metadata to explore dose-response

relationships in stroke rehabilitation[J]. Stroke，2014，

45（7）：2053-2058.

[43] MEHRHOLZ J，POHL M，PLATZ T，et al.

Electromechanical and robot-assisted arm training

for improving activities of daily living，arm

function，and arm muscle strength after stroke[J/OL].

Cochrane Database Sys t Rev，2018，9：Cd006876.

https：//doi.org/10.1002/14651858.CD006876.pub5.

[44] BERNHARDT J，HAYWARD K S，KWAKKEL

G，et al. Agreed definitions and a shared vision for

new standards in stroke recovery research：The

Stroke Recovery And Rehabilitation Roundtable

Taskforce[J]. Int J Stroke，2017，12（5）：444-450.

[45] BERNHARDT J，MEHRHOLZ J. Robotic-assisted

training after stroke：RATULS advances science[J].

Lancet，2019，394（10192）：6-8.